Jump to content

Olaparib: Revision history


For any version listed below, click on its date to view it. For more help, see Help:Page history and Help:Edit summary. (cur) = difference from current version, (prev) = difference from preceding version, m = minor edit, → = section edit, ← = automatic edit summary

(newest | oldest) View (newer 50 | ) (20 | 50 | 100 | 250 | 500)

7 September 2024

4 September 2024

26 August 2024

18 August 2024

31 July 2024

9 July 2024

7 April 2024

24 March 2024

8 March 2024

9 February 2024

11 January 2024

2 January 2024

20 December 2023

27 October 2023

12 September 2023

17 August 2023

13 August 2023

6 July 2023

10 June 2023

3 May 2023

10 April 2023

6 April 2023

7 February 2023

18 May 2022

11 April 2022

6 April 2022

28 March 2022

18 March 2022

16 March 2022

15 March 2022

1 March 2022

16 February 2022

15 February 2022

8 February 2022

  • curprev 18:4118:41, 8 February 202277.124.3.230 talk 22,178 bytes −452 →‎Mechanism of action: The deleted part misunderstood a research paper that showed that olaparib is more effective in tumor cells with high BRCA1 protein amount. More importantly - there's no reason that this should be presented as the second sentence explaining the MOA! From the paper abstract: Thus we confirmed that the amount of BRCA1 protein in the cells is a better predictor of the therapeutic effect of olaparib than its penetration into cancer tissue." undo Tags: Manual revert references removed Visual edit

3 November 2021

21 July 2021

14 May 2021

13 May 2021

27 April 2021

20 April 2021

18 April 2021

16 April 2021

  • curprev 15:4615:46, 16 April 2021103.56.5.54 talk 22,150 bytes +23 Genvio Pharmaceuticals Limited is a Bangladesh based pharmaceuticals manufacturing generic Olaparib 150 mg tablet with the brand name of Inpoza-150 and Olaparib 50 mg capsule with the brand name of Inpoza-50. undo
(newest | oldest) View (newer 50 | ) (20 | 50 | 100 | 250 | 500)